Heptares Therapeutics hires former GSK heads
pharmafile | January 12, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Atul Pande, GSK, Heptares, Roberto SolariÂ
UK and US-based clinical-stage drug firm Heptares Therapeutics has appointed Atul Pande and Roberto Solari to its board of directors.
Pande (pictured) is president of Verity BioConsulting along with being the chief medical officer at Tal Medical, a medical device company. Previously he was senior VP and a senior R&D advisor at GlaxoSmithKline.
For more than two decades he has held various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories. He is a non-executive board member of Autifony Therapeutics and serves on the scientific advisory board of Cennerv Pharma, both UK-based firms.
Solari is a visiting professor within the Infection in Airway Disease research group within the National Heart and Lung Institute at Imperial College London. Previously he also worked at GSK which he joined in 1986, and worked on inflammation and allergy drug discovery.
John Berriman, chairman of Heptares, says: “Heptares has been prolific in designing promising new drug compounds targeting well validated but previously challenging or intractable GPCRs. We are delighted to welcome Atul and Roberto to the board and will certainly benefit from their expertise in discovery and development as the company expands its drug pipeline and clinical trial activities.”
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
